JP2005530716A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005530716A5 JP2005530716A5 JP2003579755A JP2003579755A JP2005530716A5 JP 2005530716 A5 JP2005530716 A5 JP 2005530716A5 JP 2003579755 A JP2003579755 A JP 2003579755A JP 2003579755 A JP2003579755 A JP 2003579755A JP 2005530716 A5 JP2005530716 A5 JP 2005530716A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- polynucleotide
- polypeptide
- medicament
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims 18
- 102000040430 polynucleotide Human genes 0.000 claims 9
- 108091033319 polynucleotide Proteins 0.000 claims 9
- 239000002157 polynucleotide Substances 0.000 claims 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 229960005486 vaccine Drugs 0.000 claims 8
- 239000013604 expression vector Substances 0.000 claims 7
- 102000004127 Cytokines Human genes 0.000 claims 6
- 108090000695 Cytokines Proteins 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 210000000822 natural killer cell Anatomy 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 4
- 230000006907 apoptotic process Effects 0.000 claims 3
- 230000001461 cytolytic effect Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 108090000172 Interleukin-15 Proteins 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 108010002586 Interleukin-7 Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229940023041 peptide vaccine Drugs 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- -1 vaccine Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36843802P | 2002-03-27 | 2002-03-27 | |
| PCT/US2003/009707 WO2003082212A2 (en) | 2002-03-27 | 2003-03-27 | Method for treating cancer in humans |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005530716A JP2005530716A (ja) | 2005-10-13 |
| JP2005530716A5 true JP2005530716A5 (enExample) | 2006-01-12 |
Family
ID=28675491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003579755A Pending JP2005530716A (ja) | 2002-03-27 | 2003-03-27 | ヒトにおける癌の治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20050063947A1 (enExample) |
| EP (1) | EP1589990B1 (enExample) |
| JP (1) | JP2005530716A (enExample) |
| AU (1) | AU2003226141A1 (enExample) |
| CA (1) | CA2481304A1 (enExample) |
| WO (1) | WO2003082212A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610286B2 (en) | 1999-12-23 | 2003-08-26 | Zymogenetics, Inc. | Method for treating inflammation using soluble receptors to interleukin-20 |
| US7122632B2 (en) | 1999-12-23 | 2006-10-17 | Zymogenetics, Inc. | Soluble Interleukin-20 receptor |
| CA2481304A1 (en) * | 2002-03-27 | 2003-10-09 | Patrick Hwu | Method for treating cancer in humans |
| MXPA04012116A (es) * | 2002-06-07 | 2005-04-19 | Zymogenetics Inc | Uso del il-21 en cancer y otras aplicaciones terapeuticas. |
| WO2004003156A2 (en) | 2002-07-01 | 2004-01-08 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Il-21 as a regulator of immunoglobin production |
| MXPA05006117A (es) | 2002-12-13 | 2005-09-30 | Zymogenetics Inc | Produccion de il-21 en hospederos procarioticos. |
| RU2005132458A (ru) * | 2003-03-21 | 2006-03-20 | Уайт (Us) | Лечение иммунологических расстройств с использованием агонистов интерлейкина-21/рецептора интерлейкина-21 |
| US20060228331A1 (en) | 2003-10-10 | 2006-10-12 | Novo Nordisk A/S | IL-21 Derivatives and variants |
| EP1680138B1 (en) * | 2003-10-17 | 2013-07-17 | Novo Nordisk A/S | Combination therapy |
| ES2428358T3 (es) * | 2003-10-17 | 2013-11-07 | Novo Nordisk A/S | Terapia de combinación |
| EP1692276B1 (en) | 2003-11-19 | 2010-07-21 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method of inducing memory b cell development and terminal differentiation |
| AU2006237329B2 (en) | 2005-04-18 | 2012-04-12 | Novo Nordisk A/S | IL-21 variants |
| AU2006256802A1 (en) * | 2005-06-06 | 2006-12-14 | Novo Nordisk A/S | Stabilised IL-21 compositions |
| GB0519303D0 (en) | 2005-09-21 | 2005-11-02 | Oxford Biomedica Ltd | Chemo-immunotherapy method |
| US20070122413A1 (en) | 2005-11-28 | 2007-05-31 | Sivakumar Pallavur V | Il-21 antagonists |
| AU2007310777A1 (en) | 2006-10-26 | 2008-05-02 | Novo Nordisk A/S | IL-21 variants |
| EP2109620B1 (en) | 2006-12-21 | 2012-08-22 | Novo Nordisk A/S | Interleukin-21 variants with altered binding to the il-21 receptor |
| WO2008112543A2 (en) * | 2007-03-09 | 2008-09-18 | Wyeth | Rat, rabbit, and cynomolgus monkey il-21 and il-22 nucleotide and polypeptide sequences |
| CA2786891C (en) | 2009-02-20 | 2017-08-01 | Meisho.Co.,Ltd | Immunopotentiating composition and process for producing same |
| SI3409289T1 (sl) | 2010-02-26 | 2020-12-31 | Novo Nordisk A/S | Stabilni sestavki, ki vsebujejo protitelo |
| RU2012153786A (ru) | 2010-05-28 | 2014-07-10 | Ново Нордиск А/С | Стабильные многодозовые композиции, содержащие антитело и консервант |
| CA2824515C (en) | 2011-01-18 | 2022-09-13 | Bioniz, Llc | Compositions and methods for modulating gamma-c-cytokine activity |
| US9959384B2 (en) | 2013-12-10 | 2018-05-01 | Bioniz, Llc | Methods of developing selective peptide antagonists |
| GB201405834D0 (en) * | 2014-04-01 | 2014-05-14 | Univ London Queen Mary | Oncolytic virus |
| KR102586707B1 (ko) * | 2014-10-01 | 2023-10-11 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 항원 및 어쥬번트로서 인터류킨-21을 갖는 백신 |
| WO2016138340A1 (en) * | 2015-02-27 | 2016-09-01 | Saint Louis University | Tumor suppressor sall1 as a therapeutic agent for treating cancer |
| EP3978512A1 (en) | 2015-10-09 | 2022-04-06 | Bioniz, LLC | Modulating gamma-c-cytokine activity |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| KR102707650B1 (ko) | 2017-04-07 | 2024-09-19 | 바이오니즈 테라퓨틱스, 아이엔씨. | 감마-c-사이토카인 활성의 안정한 조절자 |
| KR20190141695A (ko) | 2017-04-13 | 2019-12-24 | 센티 바이오사이언시스, 인코포레이티드 | 병용 암 면역요법 |
| KR102920712B1 (ko) | 2017-05-24 | 2026-01-30 | 노파르티스 아게 | 항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법 |
| CN109554353B (zh) * | 2017-09-26 | 2021-08-06 | 杭州康万达医药科技有限公司 | 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
| GB201816547D0 (en) | 2018-10-10 | 2018-11-28 | Univ London Queen Mary | Oncolytic virus for the treatment of cancer |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| CA3116138A1 (en) | 2018-10-17 | 2020-04-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| BR112021021878A2 (pt) | 2019-05-03 | 2022-01-18 | Bioniz Llc | Modulação dos efeitos de sinalização da gama-c-citocina para tratamento da alopecia e distúrbios associados |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| DE69332197T2 (de) * | 1992-03-13 | 2003-04-17 | Organon Teknika B.V., Boxtel | Epstein-Barr-Virus verwandte Peptide und Nukleinsäuresegmenten |
| US7189400B2 (en) * | 1998-03-17 | 2007-03-13 | Genetics Institute, Llc | Methods of treatment with antagonists of MU-1 |
| US20010023070A1 (en) * | 1998-05-29 | 2001-09-20 | Reinhard Ebner | Interleukins-21 and 22 |
| JP2002516103A (ja) * | 1998-05-29 | 2002-06-04 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | インターロイキン２１およびインターロイキン２２ |
| US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| US6312924B1 (en) * | 1999-03-18 | 2001-11-06 | Zymogenetics, Inc. | Murine interferon-α |
| US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| ES2279809T3 (es) * | 2000-04-05 | 2007-09-01 | Zymogenetics, Inc. | Receptores de citoquina zalfa11 solubles. |
| EP1309627B1 (en) * | 2000-08-08 | 2009-09-30 | Immunomedics, Inc. | Immunotherapy for chronic myelocytic leukemia with naked anti-nca-90 antibody |
| US20040260061A1 (en) * | 2001-03-12 | 2004-12-23 | Keld Kaltoft | Continuous, normal human t-lymphocyte cell lines comprising a recombinant immune receptor with defined antigen specificity |
| EP3254687A1 (en) * | 2001-10-04 | 2017-12-13 | Genetics Institute LLC | Methods and compositions for modulating interleukin-21 receptor activity |
| CA2481304A1 (en) * | 2002-03-27 | 2003-10-09 | Patrick Hwu | Method for treating cancer in humans |
-
2003
- 2003-03-27 CA CA002481304A patent/CA2481304A1/en not_active Abandoned
- 2003-03-27 WO PCT/US2003/009707 patent/WO2003082212A2/en not_active Ceased
- 2003-03-27 US US10/508,978 patent/US20050063947A1/en not_active Abandoned
- 2003-03-27 EP EP03745667A patent/EP1589990B1/en not_active Revoked
- 2003-03-27 JP JP2003579755A patent/JP2005530716A/ja active Pending
- 2003-03-27 AU AU2003226141A patent/AU2003226141A1/en not_active Abandoned
-
2010
- 2010-01-04 US US12/651,858 patent/US20100135958A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lin et al. | Therapeutic hpv DNA vaccines | |
| Masihi | Fighting infection using immunomodulatory agents | |
| Zlotnik et al. | Interleukin 10 | |
| EP1589990B1 (en) | Il-21 for use in treating cancer | |
| JP2006141398A5 (enExample) | ||
| RU2000131593A (ru) | Селективные агонисты и антагонисты il-2. | |
| JP2006020648A5 (enExample) | ||
| Tan et al. | Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model | |
| Moschella et al. | Combination strategies for enhancing the efficacy of immunotherapy in cancer patients | |
| EP1728863A3 (en) | C-class oligonucleotide analogs with enhanced immunostimulatory potency | |
| KR101652767B1 (ko) | Ｉｌ-28을 이용한 백신 및 면역치료제, 및 그를 사용하는 방법 및 조성물 | |
| JP2009544724A5 (enExample) | ||
| US9999666B2 (en) | Uses of conjugates of GM-CSF and IL-7 to treat viral infections | |
| HUP0402259A2 (hu) | Vakcinák | |
| Shurin et al. | Antitumor activities of IL-12 and mechanisms of action | |
| Agha-Mohammadi et al. | Immunomodulation of cancer: potential use of selectively replicating agents | |
| Wang et al. | Innate endogenous adjuvants prime to desirable immune responses via mucosal routes | |
| Mikysková et al. | Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF | |
| Zhang et al. | An adenoviral vector expressing functional heterogeneous proteins herpes simplex viral thymidine kinase and human interleukin-2 has enhanced in vivo antitumor activity against medullary thyroid carcinoma. | |
| Namkoong et al. | Enhancement of antigen-specific CD8 T cell responses by co-delivery of Fc-fused CXCL11 | |
| JP2006502228A5 (enExample) | ||
| JP2005512518A5 (enExample) | ||
| RU2007118675A (ru) | Сочетание рекомбинантной микробактерии и биологически активного средства в качестве вакцины | |
| JP2004507445A (ja) | 白血病、リンパ腫、及び充実性腫瘍のための温熱療法及び免疫療法 | |
| Decker et al. | Cytokine adjuvants for vaccine therapy of neoplastic and infectious disease |